26 February 2025
26 February 2025
Organovo’s lead asset FXR314 will be investigated in a Phase II trial for inflammatory bowel disease (IBD).
Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.
The companies will work together to develop small molecules using BridGene’s chemoproteomics platform.
Entrada plans to initiate the Phase Ib study of ENTR-601-44 in the US in the first half of next year.
The approval is intended for adults and adolescents aged 12 years and above.
The decision is supported by outcomes from the Phase III IMROZ study.
The decision was based on outcomes from the Phase Ib Honeycomb trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
